Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Analysis of the genome to personalize therapy for melanoma.

Davies MA, Samuels Y.

Oncogene. 2010 Oct 14;29(41):5545-55. doi: 10.1038/onc.2010.323. Epub 2010 Aug 9. Review.

2.

Targeted therapy for melanoma: a primer.

Davies MA, Gershenwald JE.

Surg Oncol Clin N Am. 2011 Jan;20(1):165-80. doi: 10.1016/j.soc.2010.09.003. Review.

3.

[Therapeutic approaches in Melanoma - a paradigm for personalized medicine].

Dummer R, Goldinger S, Rinderknecht J, Eggmann N, Felderer L, Braun R, French LE.

Praxis (Bern 1994). 2012 Jul 25;101(15):955-9. doi: 10.1024/1661-8157/a001005. Review. German.

PMID:
22811327
4.

Genetic aberrations in primary esophageal melanomas: molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases.

Langer R, Becker K, Feith M, Friess H, Höfler H, Keller G.

Mod Pathol. 2011 Apr;24(4):495-501. doi: 10.1038/modpathol.2010.220. Epub 2010 Dec 3.

5.

Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.

Bradish JR, Montironi R, Lopez-Beltran A, Post KM, MacLennan GT, Cheng L.

Future Oncol. 2013 Feb;9(2):245-53. doi: 10.2217/fon.12.179. Review.

PMID:
23414474
6.

Molecular profiling of melanoma and the evolution of patient-specific therapy.

Gajewski TF.

Semin Oncol. 2011 Apr;38(2):236-42. doi: 10.1053/j.seminoncol.2011.01.004. Review.

7.

Ras, Raf, and MAP kinase in melanoma.

Solus JF, Kraft S.

Adv Anat Pathol. 2013 Jul;20(4):217-26. doi: 10.1097/PAP.0b013e3182976c94. Review.

PMID:
23752084
8.

Molecular biology of melanoma.

Swick JM, Maize JC Sr.

J Am Acad Dermatol. 2012 Nov;67(5):1049-54. doi: 10.1016/j.jaad.2011.06.047. Epub 2012 Mar 28. Review.

PMID:
22459362
9.

Molecular testing in malignant melanoma.

Grossmann AH, Grossmann KF, Wallander ML.

Diagn Cytopathol. 2012 Jun;40(6):503-10. doi: 10.1002/dc.22810. Review.

PMID:
22619125
10.

Novel somatic mutations to PI3K pathway genes in metastatic melanoma.

Shull AY, Latham-Schwark A, Ramasamy P, Leskoske K, Oroian D, Birtwistle MR, Buckhaults PJ.

PLoS One. 2012;7(8):e43369. doi: 10.1371/journal.pone.0043369. Epub 2012 Aug 17.

11.

[Genetic diversity and immunological characteristics of malignant melanoma: the therapeutic spectrum].

Doma V, Gulya E.

Orv Hetil. 2015 Apr;156(15):583-91. doi: 10.1556/OH.2015.30122. Review. Hungarian.

PMID:
25845317
12.

Treatment implications of the emerging molecular classification system for melanoma.

Romano E, Schwartz GK, Chapman PB, Wolchock JD, Carvajal RD.

Lancet Oncol. 2011 Sep;12(9):913-22. doi: 10.1016/S1470-2045(10)70274-6. Epub 2011 Feb 23. Review.

PMID:
21349766
13.

Cytogenetic and mutational analyses of melanocytic tumors.

Gerami P, Busam KJ.

Dermatol Clin. 2012 Oct;30(4):555-66, v. doi: 10.1016/j.det.2012.06.015. Epub 2012 Aug 21. Review.

PMID:
23021045
14.

KIT pathway alterations in mucosal melanomas of the vulva and other sites.

Omholt K, Grafström E, Kanter-Lewensohn L, Hansson J, Ragnarsson-Olding BK.

Clin Cancer Res. 2011 Jun 15;17(12):3933-42. doi: 10.1158/1078-0432.CCR-10-2917.

15.

Targeted therapy for melanoma: rational combinatorial approaches.

Kwong LN, Davies MA.

Oncogene. 2014 Jan 2;33(1):1-9. doi: 10.1038/onc.2013.34. Epub 2013 Feb 18. Review.

PMID:
23416974
16.

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.

Willmore-Payne C, Holden JA, Tripp S, Layfield LJ.

Hum Pathol. 2005 May;36(5):486-93.

PMID:
15948115
17.

Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.

Henary H, Hong DS, Falchook GS, Tsimberidou A, George GC, Wen S, Wheler J, Fu S, Naing A, Piha-Paul S, Janku F, Kim KB, Hwu P, Kurzrock R.

Ann Oncol. 2013 Aug;24(8):2158-65. doi: 10.1093/annonc/mdt115. Epub 2013 Apr 10.

18.

Recent discoveries in the genetics of melanoma and their therapeutic implications.

Marquette A, Bagot M, Bensussan A, Dumaz N.

Arch Immunol Ther Exp (Warsz). 2007 Nov-Dec;55(6):363-72. Epub 2007 Dec 3. Review.

19.

KIT amplification and gene mutations in acral/mucosal melanoma in Korea.

Yun J, Lee J, Jang J, Lee EJ, Jang KT, Kim JH, Kim KM.

APMIS. 2011 Jun;119(6):330-5. doi: 10.1111/j.1600-0463.2011.02737.x. Epub 2011 Mar 24.

PMID:
21569090
20.

Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.

Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, Saida T, Ferrone S, Takata M, Uhara H, Okuyama R.

Br J Cancer. 2012 Feb 28;106(5):939-46. doi: 10.1038/bjc.2012.12. Epub 2012 Jan 26.

Items per page

Supplemental Content

Write to the Help Desk